Results 191 to 200 of about 124,112 (267)

LMDmapper: an open-source desktop tool for spatial mapping of laser microdissection samples. [PDF]

Open Res Eur
Alberdi A, Ramirez J, Gaun N, Horisberger Z, Wang B, Trivedi U, Bogri A.   +6 more
europepmc   +1 more source

Four Questions for Ethnographers Under Trumpian Authoritarianism

American Anthropologist, EarlyView.
ABSTRACT This article examines evolving challenges and ethical dilemmas facing ethnographers working under intensifying authoritarianism in the United States. Because very little of what the United States is experiencing is new, my work here is primarily curatorial in nature, drawing upon the lessons offered by scholars across disciplines in the United
Elizabeth Hanna Rubio
wiley   +1 more source

Genomic advances in orphan and underutilized Brassicaceae crops and their wild relatives. [PDF]

Front Plant Sci
Amas J, Natarajan RK, Thomas WJW, Edwards D, Batley J, Dolatabadian A.   +5 more
europepmc   +1 more source

The unbearable (financial) burdens of parenting

The British Journal of Sociology, EarlyView.
Alya Guseva
wiley   +1 more source

Genetic risk factors in Finnish patients with Fuchs endothelial corneal dystrophy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To study the genetic risk factors of Fuchs endothelial corneal dystrophy (FECD) in the Finnish population using hospital‐based and large biobank cohorts. Methods We genotyped a cohort of 107 Finnish patients with FECD for the primary associated genetic risk factor, the TCF4 (CTG)>50 expansion, and studied their clinical phenotype.
Inka‐Tuulevi Vähämäki, Annamari T. Immonen, Joel T. Rämö, Aino M. Jaakkola, Kari Krootila, Maria Kaukonen, FinnGen, Aarno Palotie, Hannes Lohi, Tero T. Kivelä, Joni A. Turunen   +10 more
wiley   +1 more source

Completion and outcomes of postmarketing requirements and commitments issued by the US Food and Drug Administration for new drugs, 2016-24: cross sectional evaluation of postmarketing studies. [PDF]

BMJ Med
Siebert M, McGonigle R, Gutiérrez-Sacristán A, Naci H, Wagner AK, Bourgeois FT.   +5 more
europepmc   +1 more source

Tick‐Borne Encephalitis (TBE) Vaccine in the National Immunisation Programme—For Whom, When and Where?

Acta Paediatrica, EarlyView.
ABSTRACT The incidence of Tick‐borne encephalitis (TBE) cases has increased. The presumed location of transmission of Tick‐borne encephalitis virus (TBEV) has been expanding increasingly in the western parts of Europe during the past decade. There has also been an increased incidence of surveillance‐reported TBE cases in southern Sweden and southern ...
H. H. Askling, D. Zavadska
wiley   +1 more source

What Drives Public Preference for Rare Drugs Coverage in China? Insights From a Multi-Center Discrete Choice Experiment. [PDF]

Health Expect
Wu Y, Chen J, Shao J, Peng H, Li L, Chen G, Li S.   +6 more
europepmc   +1 more source

Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial

British Journal of Haematology, EarlyView.
Summary Avatrombopag treatment resulted in significantly higher platelet response rates in patients when compared with placebo in a phase 3b study of patients with paediatric immune thrombocytopenia (ITP) (NCT04516967). These post hoc analyses of the 12‐week core phase further assessed the efficacy of avatrombopag, considering the influence of baseline
Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Sule Unal, John Grainger, Amanda B. Grimes, Michele P. Lambert, Jessica Zhang, Brian D. Jamieson, Faizan Sattar, Scott Kolodny, Michael Vredenburg, on behalf of the AVA‐PED‐301 Study Group   +12 more
wiley   +1 more source

Medical device development and innovation for rare and pediatric populations: a global landscape overview. [PDF]

Orphanet J Rare Dis
Dooms M, O'Connor D, Melvin T, Mueller F, Peiris V, Pohlson K, Wong-Rieger D, Jonker AH, IRDiRC WG Medical Technologies for Rare Diseases.   +8 more
europepmc   +1 more source